Referencias►
1.
DiLorenzo PA. Pellagra-like syndrome associated with isoniazid therapy.
Acta Derm Venereol. 1967;47:318 - 322.
2.
Ishii N, Nishihara Y. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy.
J Neurol Neurosurg Psychiatry.
1985;48:628 - 634.
3.
Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Arch Intern Med. 1994;154:1586 - 1595.
4.
Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Am J Cardiol. 1998;82:737 - 743.
5.
Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
Arch Intern Med. 1994;154:73 - 82.
6.
Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
Am J Kidney Dis. 1995;25:616 - 622.
7.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin.
J Am Coll Cardiol. 1986;8:1245 - 1255.
8.
Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol.
Arch Intern Med.
2000;160:1177 - 1184.
9.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial.
JAMA
2000;284:1263 - 1270.
10.
Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial.
J Cardiovasc Pharmacol Ther. 1996;1:195 - 202.
11.
Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide.
J Pediatr Endocrinol Metab. 1996;9:501 - 509.
12.
Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Diabetologia. 1995;38:848 - 852.
13.
Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas.
Acta Diabetol. 1998;35:61 - 64.
14.
Head KA. Inositol hexaniacinate: a safer alternative to niacin.
Altern Med Rev. 1996;1:176 - 184.
15.
Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
Clin Rheumatol. 1988;7:46 - 49.
16.
Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study.
Inflamm Res.
1996;45:330 - 334.
17.
Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study.
Br J Dermatol.
1986;115:77 - 80.
18.
Kellman M. Bursitis: a new chemotherapeutic approach.
J Am Osteopathic Assoc. 1962;61:896 - 903.
19.
Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies. Two nutrition intervention trials.
Arch Ophthamol. 1993;111:1246 - 1253.
20.
Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection.
Am JEpidemiol.
1996;143:1244 - 1256.
21.
Tang AM, Graham NHM, Kirby AJ, et al. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men.
Am JEpidemiol.
1993;138:937 - 951.
22.
Doyle W, Crawford MA, Wynn AH, et al. The association between maternal diet and birth dimensions.
J Nutr Med. 1990;1:9 - 17.
23.
Kunin RA. Manganese and niacin in the treatment of drug-induced tardive dyskinesias. J Orthomol Psychiatry 5:4-27, 1976. In: Werbach MR.
Nutritional Influences on Illness
[book on CD-ROM]
.
2nd ed. Tarzana, CA. 1996.
24.
Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Arch Intern Med. 1994;154:1586 - 1595.
25.
Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
Am J Cardiol. 1998;82:737 - 743.
26.
Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
Arch Intern Med. 1994;154:73 - 82.
27.
Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
Am J Kidney Dis. 1995;25:616 - 622.
28.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial.
JAMA. 2000;284:1263 - 1270.
29.
Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial.
J Cardiovasc Pharmacol Ther. 1996;1:195 - 202.
30.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin.
J Am Coll Cardiol. 1986;8:1245 - 1255.
31.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial.
JAMA
2000;284:1263 - 1270.
32.
Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide.
J Pediatr Endocrinol Metab. 1996;9:501 - 509.
33.
Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
Diabetes. 1998;47:980 - 984.
34.
Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Diabetologia. 1995;38:848 - 852.
35.
Ludvigsson J, Samuelsson U, Johansson C, et al. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study.
Diabetes Metab Res Rev. 2001;17:131 - 136.
36.
Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas.
Acta Diabetol. 1998;35:61 - 64.
37.
O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
Br J Clin Pract. 1988;42:377 - 383.
38.
Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial.
Br J Clin Pract. 1988;42:141 - 145.
39.
Head A. Treatment of intermittent claudication with inositol nicotinate.
Practitioner. 1986;230:49 - 54.
40.
Tyson VC. Treatment of intermittent claudication.
Practitioner. 1979;223:121 - 126.
41.
O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
Br J Clin Pract. 1988;42:377 - 383.
42.
Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study.
Inflamm Res.
1996;45:330 - 334.
43.
Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
Clin Rheumatol. 1988;7:46 - 49.
44.
Gibbons LW, Gonzalez V, Gordon N, at al. The prevalence of side effects with regular and sustained-release nicotinic acid.
Am J Med. 1995;99:378 - 385.
45. Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 1999:1507.
46.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial.
JAMA. 2000;284:1263 - 1270.
47.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D - 29D.
48.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated.
J Am Coll Cardiol.
2000;35(suppl A):326.
49.
Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
Am J Cardiol. 2001;87:476 - 479.
50.
Bourgeois BFD, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide.
Neurology.
1982;32:1122 - 1126.
51.
Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B
6, Folate, Vitamin B
12, Pantothenic Acid, Biotin, and Choline (1998). Available at www.nap.edu. Accessed October 4, 2001.
52.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D - 29D.
53.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated.
J Am Coll Cardiol.
2000;35(suppl A):326.
54.
Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
Am J Cardiol.
2001;87:476 - 479.
55.
Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy.
Am Heart J.
2002;143:514 - 518.
56.
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Arch Intern Med. 2002;162:1568-1576.
57.
Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics.
Can Psychiatr Assoc J. 1973;18:377 - 383.
58.
Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy.
Psychosomatics.
1970;11:517 - 521.
59.
Hoffer A. Megavitamin B-3 therapy for schizophrenia.
Can Psychiatr Assoc J.
1971;16:499 - 504.
60.
Newbold HL, Mosher LR. Niacin and the schizophrenic patient.
Am J Psychiatry.
1970;127:535 - 536.
61.
Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role?
Drugs.
1985;30:58 - 65.
62.
Procter A. Enhancement of recovery from psychiatric illness by methylfolate.
Br J Psychiatry. 1991;159:271 - 272.
63.
Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia.
Arch Gen Psychiatry. 1973;28:308 - 315.